However, genetic dissection of this pathway, particularly its upstream regulator IL-23, in preclinical NASH models is lacking and the target candidacy of this IL-17/IL-23 axis in NASH is yet to be fully established. Here, IL23A is linked to metabolic dysfunction-associated steatohepatitis.